A novel human tumor endothelial marker 1 targeting antibody-drug conjugate for treatment of cancer
An Italian SME specialized in drug discovery has developed and patented a human tumor endothelial marker 1 (TEM1) targeting antibody-drug conjugate (ADC) for treating cancer. This molecule has shown therapeutic efficacy combined with a good safety profile. The company is looking for pharmaceutical companies or investors for financial or license agreement to further develop the product in clinical trials. A research cooperation agreement is also foreseen.